XML 36 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 1 Months Ended | 11 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jan. 29, 2020 | Dec. 31, 2020 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |  |  |
Pay vs Performance Disclosure, Table |  |  | Pay Versus Performance Disclosure As required by the Dodd-Frank Act and Item 402(v) of Regulation S-K, the Pay versus Performance disclosure that follows provides information about the relationship between Compensation Actually Paid (“CAP”), to our Principal Executive Officer (“PEO”), and Non-PEO NEOs and certain financial performance measures of the Company. See the Compensation Discussion and Analysis within this Proxy Statement for further information concerning the Company’s variable pay-for-performance philosophy and how the Company aligns executive compensation with Company performance.
| Year |  |  | Summary Compensation Table Total for PEO (Blanchard) (a) |  |  | Summary Compensation Table Total for Other PEO (Darling) (b) |  |  | Compensation Actually Paid to PEO (Blanchard) (a) |  |  | Compensation Actually Paid to Other PEO (Darling) (b) |  |  | Average Summary Compensation Table Total for non-PEO NEOs (c) |  |  | Average Compensation Actually Paid to non-PEO NEOs (c) |  |  | Value of Initial Fixed $100 Investment Based on: |  |  | Net Income ($mm) (d) |  |  | Revenue ($mm) (e) |
| Total Shareholder Return (e) |  |  | Peer Total Shareholder Return (e) |
| 2024 |  |  | $5,103,466 |  |  | N/A |  |  | $2,531,827 |  |  | N/A |  |  | $1,805,308 |  |  | ​$850,008 |  |  | $32 |  |  | $114 |  |  | ($56) |  |  | $120 |
| 2023 |  |  | $4,459,800 |  |  | N/A |  |  | $1,870,227 |  |  | N/A |  |  | $1,405,306 |  |  | $877,307 |  |  | $44 |  |  | $115 |  |  | ($83) |  |  | $167 |
| 2022 |  |  | $5,940,722 |  |  | N/A |  |  | $3,599,763 |  |  | N/A |  |  | $1,739,011 |  |  | $1,406,419 |  |  | $57 |  |  | $111 |  |  | ($15) |  |  | $156 |
| 2021 |  |  | $4,202,608 |  |  | N/A |  |  | $1,818,313 |  |  | N/A |  |  | $1,234,846 |  |  | $1,051,797 |  |  | $69 |  |  | $125 |  |  | $4 |  |  | $148 |
| 2020 |  |  | $10,029,434 |  |  | $288,753 |  |  | $10,513,388 |  |  | ($7,088,313) |  |  | $1,411,154 |  |  | $772,039 |  |  | $87 |  |  | $126 |  |  | ($24) |  |  | $130 |
(a) | Dr. Blanchard served as interim CEO for part of 2020 and was appointed President and CEO in April 2020.
(b) | Mr. Darling, CEO at the beginning of 2020, passed away unexpectedly in January 2020. All of Mr. Darling’s unvested equity was forfeited upon his death.
(c) | NEOs in 2024 include Messrs. Colleran, Griffin and Levitz and Ms. Nunes. Mr. Levitz resigned from his role as the Company’s EVP, CFO and Treasurer in June 2024, and separated from service with the Company on December 31, 2024. Mr. Griffin joined the Company as EVP, CFO and Treasurer in June 2024. NEOs in 2023 include Messrs. Levitz and Colleran and Ms. Nunes. NEOs in 2022 include Messrs. Levitz and Colleran. NEOs in 2021 include Messrs. Levitz, Colleran, Thomas Finnerty and James Loerop. Mr. Loerop, the Company’s EVP, Business Development and Strategic Planning, resigned in January 2022. Mr. Finnerty, the Company’s EVP, Human Resources, retired in March 2022. NEOs in 2020 include Messrs. Levitz, Colleran, Finnerty, Loerop and Sylvia Cheung. Ms. Cheung, the Company’s CFO, resigned in August 2020. Mr. Colleran joined the Company as EVP, General Counsel and Secretary in March 2020, and Mr. Levitz joined Company as EVP, CFO and Treasurer in August 2020. Ms. Nunes joined the Company in September 2021 and was named SVP, Chief Operations Officer in June 2023.
(d) | Shareholder return is based on $100 investment at the beginning of 2020. Peer shareholder return is based on the NASDAQ Biotechnology Index.
(e) | Net Income and Revenue are as reported in the Company’s Annual Report on Form 10-K. Revenue for the years ended December 31, 2024, 2023 and 2022 include revenue from continuing operations and excludes revenue from discontinued operations relating to the sale of the Company’s subsidiary, Arthrosurface Incorporated, in October 2024, and the planned divestiture of the Company’s subsidiary, Parcus Medical, LLC (which was completed in Q1 2025). More information regarding revenue from discontinued operations is listed in Note 3 of Notes to Consolidated Financial Statements in the company's Annual Report on Form 10-K for the year ended December 31, 2024.
The following table sets forth a reconciliation from the summary compensation table (SCT) to compensation actually paid (CAP) to our PEO and to our average non-PEO NEO each year.
|  |  |  | PEO (Blanchard) |  |  | PEO (Darling) |  |  | (Average NEO) |
|  |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |  |  | 2020 |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
| SCT Total Compensation |  |  | $5,103,466 |  |  | $4,459,800 |  |  | $5,940,722 |  |  | $4,202,608 |  |  | $10,029,434 |  |  | $288,753 |  |  | $1,805,308 |  |  | $1,405,306 |  |  | $1,739,011 |  |  | $1,234,846 |  |  | $1,411,154 |
| SUBTRACT Grant Fair Value of Equity Awards Made During Current Year(a) |  |  | ($3,833,108) |  |  | ($3,124,444) |  |  | ($4,630,341) |  |  | ($2,942,637) |  |  | ($8,994,889) |  |  | $0 |  |  | ($1,169,352) |  |  | ($719,959) |  |  | ($1,051,440) |  |  | ($658,333) |  |  | ($962,952) |
| ADD Year End Fair Value of Equity Awards Made During Current Year(b) |  |  | $2,096,033 |  |  | $2,457,454 |  |  | $5,294,178 |  |  | $3,254,974 |  |  | $9,337,528 |  |  | $0 |  |  | $​482,698 |  |  | $568,766 |  |  | $1,205,238 |  |  | $728,209 |  |  | $668,806 |
| ADD Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards(c) |  |  | ($1,148,160) |  |  | ($1,421,814) |  |  | ($1,016,462) |  |  | ($2,470,476) |  |  | $0 |  |  | $0 |  |  | ($​95,541) |  |  | ($252,244) |  |  | ($274,828) |  |  | ($189,171) |  |  | ($64,142) |
| ADD Change in Fair Value of Equity Awards Granted in Prior Years that Vested in Current Year(d) |  |  | $313,596 |  |  | ($500,768) |  |  | ($1,988,334) |  |  | ($226,155) |  |  | $0 |  |  | ($18,351) |  |  | $44,901 |  |  | ($124,563) |  |  | ($211,562) |  |  | ($63,754) |  |  | ($83,186) |
| ADD Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year(e) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $141,315 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |
| SUBTRACT Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year(f) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($7,358,716) |  |  | ($​218,005) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($197,641) |
| Total Adjustments Related to Equity Awards |  |  | ($2,571,639) |  |  | ($2,589,573) |  |  | ($2,340,959) |  |  | ($2,384,295) |  |  | $483,954 |  |  | ($7,377,066) |  |  | ($​955,299) |  |  | ($527,999) |  |  | ($332,592) |  |  | ($183,048) |  |  | ($639,115) |
| Compensation Actually Paid Total |  |  | $2,531,827 |  |  | $1,870,227 |  |  | $3,599,763 |  |  | $1,818,313 |  |  | $10,513,388 |  |  | ($7,088,313) |  |  | ​$​850,008 |  |  | $877,307 |  |  | $1,406,419 |  |  | $1,051,797 |  |  | $772,039 |
(a) | Represents the grant date fair value of equity-based awards made during the fiscal year.
(b) | Represents the year-end fair value of equity awards that were made during the fiscal year.
(c) | Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end.
(d) | Represents the change in fair value since prior year-end of equity-based awards granted in prior fiscal years that vested during the current fiscal year.
(e) | Represents the fair value on the vesting date of equity-based awards that vested in the same year as granted. In 2020, Dr. Blanchard received a grant of RSUs for her service as interim Chief Executive Officer between February and April 2020, which RSUs fully vested upon her permanent appointment as President and CEO in April 2020.
(f) | Represents the prior year-end fair value of equity awards that were forfeited by other PEOs who terminated during the year. Mr. Darling passed away unexpectedly in early 2020, and unvested equity awards were forfeited upon his death. Ms. Cheung resigned in August 2020 and all unvested equity awards were forfeited upon her resignation. Mr. Levitz resigned his position as Executive Vice President, Chief Financial Officer and Treasurer in June 2024, and separated from service with the Company as of December 31, 2024, at which time all of his unvested equity awards were forfeited.
Company Selected Measure Name |  |  | Revenue |  |  |  |
Named Executive Officers, Footnote |  |  |
(a) | Dr. Blanchard served as interim CEO for part of 2020 and was appointed President and CEO in April 2020.
(b) | Mr. Darling, CEO at the beginning of 2020, passed away unexpectedly in January 2020. All of Mr. Darling’s unvested equity was forfeited upon his death.
(c) | NEOs in 2024 include Messrs. Colleran, Griffin and Levitz and Ms. Nunes. Mr. Levitz resigned from his role as the Company’s EVP, CFO and Treasurer in June 2024, and separated from service with the Company on December 31, 2024. Mr. Griffin joined the Company as EVP, CFO and Treasurer in June 2024. NEOs in 2023 include Messrs. Levitz and Colleran and Ms. Nunes. NEOs in 2022 include Messrs. Levitz and Colleran. NEOs in 2021 include Messrs. Levitz, Colleran, Thomas Finnerty and James Loerop. Mr. Loerop, the Company’s EVP, Business Development and Strategic Planning, resigned in January 2022. Mr. Finnerty, the Company’s EVP, Human Resources, retired in March 2022. NEOs in 2020 include Messrs. Levitz, Colleran, Finnerty, Loerop and Sylvia Cheung. Ms. Cheung, the Company’s CFO, resigned in August 2020. Mr. Colleran joined the Company as EVP, General Counsel and Secretary in March 2020, and Mr. Levitz joined Company as EVP, CFO and Treasurer in August 2020. Ms. Nunes joined the Company in September 2021 and was named SVP, Chief Operations Officer in June 2023.
Peer Group Issuers, Footnote |  |  |
(d) | Shareholder return is based on $100 investment at the beginning of 2020. Peer shareholder return is based on the NASDAQ Biotechnology Index.
Adjustment To PEO Compensation, Footnote |  |  | The following table sets forth a reconciliation from the summary compensation table (SCT) to compensation actually paid (CAP) to our PEO and to our average non-PEO NEO each year.
|  |  |  | PEO (Blanchard) |  |  | PEO (Darling) |  |  | (Average NEO) |
|  |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |  |  | 2020 |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
| SCT Total Compensation |  |  | $5,103,466 |  |  | $4,459,800 |  |  | $5,940,722 |  |  | $4,202,608 |  |  | $10,029,434 |  |  | $288,753 |  |  | $1,805,308 |  |  | $1,405,306 |  |  | $1,739,011 |  |  | $1,234,846 |  |  | $1,411,154 |
| SUBTRACT Grant Fair Value of Equity Awards Made During Current Year(a) |  |  | ($3,833,108) |  |  | ($3,124,444) |  |  | ($4,630,341) |  |  | ($2,942,637) |  |  | ($8,994,889) |  |  | $0 |  |  | ($1,169,352) |  |  | ($719,959) |  |  | ($1,051,440) |  |  | ($658,333) |  |  | ($962,952) |
| ADD Year End Fair Value of Equity Awards Made During Current Year(b) |  |  | $2,096,033 |  |  | $2,457,454 |  |  | $5,294,178 |  |  | $3,254,974 |  |  | $9,337,528 |  |  | $0 |  |  | $​482,698 |  |  | $568,766 |  |  | $1,205,238 |  |  | $728,209 |  |  | $668,806 |
| ADD Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards(c) |  |  | ($1,148,160) |  |  | ($1,421,814) |  |  | ($1,016,462) |  |  | ($2,470,476) |  |  | $0 |  |  | $0 |  |  | ($​95,541) |  |  | ($252,244) |  |  | ($274,828) |  |  | ($189,171) |  |  | ($64,142) |
| ADD Change in Fair Value of Equity Awards Granted in Prior Years that Vested in Current Year(d) |  |  | $313,596 |  |  | ($500,768) |  |  | ($1,988,334) |  |  | ($226,155) |  |  | $0 |  |  | ($18,351) |  |  | $44,901 |  |  | ($124,563) |  |  | ($211,562) |  |  | ($63,754) |  |  | ($83,186) |
| ADD Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year(e) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $141,315 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |
| SUBTRACT Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year(f) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($7,358,716) |  |  | ($​218,005) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($197,641) |
| Total Adjustments Related to Equity Awards |  |  | ($2,571,639) |  |  | ($2,589,573) |  |  | ($2,340,959) |  |  | ($2,384,295) |  |  | $483,954 |  |  | ($7,377,066) |  |  | ($​955,299) |  |  | ($527,999) |  |  | ($332,592) |  |  | ($183,048) |  |  | ($639,115) |
| Compensation Actually Paid Total |  |  | $2,531,827 |  |  | $1,870,227 |  |  | $3,599,763 |  |  | $1,818,313 |  |  | $10,513,388 |  |  | ($7,088,313) |  |  | ​$​850,008 |  |  | $877,307 |  |  | $1,406,419 |  |  | $1,051,797 |  |  | $772,039 |
(a) | Represents the grant date fair value of equity-based awards made during the fiscal year.
(b) | Represents the year-end fair value of equity awards that were made during the fiscal year.
(c) | Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end.
(d) | Represents the change in fair value since prior year-end of equity-based awards granted in prior fiscal years that vested during the current fiscal year.
(e) | Represents the fair value on the vesting date of equity-based awards that vested in the same year as granted. In 2020, Dr. Blanchard received a grant of RSUs for her service as interim Chief Executive Officer between February and April 2020, which RSUs fully vested upon her permanent appointment as President and CEO in April 2020.
(f) | Represents the prior year-end fair value of equity awards that were forfeited by other PEOs who terminated during the year. Mr. Darling passed away unexpectedly in early 2020, and unvested equity awards were forfeited upon his death. Ms. Cheung resigned in August 2020 and all unvested equity awards were forfeited upon her resignation. Mr. Levitz resigned his position as Executive Vice President, Chief Financial Officer and Treasurer in June 2024, and separated from service with the Company as of December 31, 2024, at which time all of his unvested equity awards were forfeited.
Non-PEO NEO Average Total Compensation Amount |  |  | $ 1,805,308 | $ 1,405,306 | $ 1,739,011 | $ 1,234,846 | $ 1,411,154
Non-PEO NEO Average Compensation Actually Paid Amount |  |  | $ 850,008 | 877,307 | 1,406,419 | 1,051,797 | 772,039
Adjustment to Non-PEO NEO Compensation Footnote |  |  | The following table sets forth a reconciliation from the summary compensation table (SCT) to compensation actually paid (CAP) to our PEO and to our average non-PEO NEO each year.
|  |  |  | PEO (Blanchard) |  |  | PEO (Darling) |  |  | (Average NEO) |
|  |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |  |  | 2020 |  |  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
| SCT Total Compensation |  |  | $5,103,466 |  |  | $4,459,800 |  |  | $5,940,722 |  |  | $4,202,608 |  |  | $10,029,434 |  |  | $288,753 |  |  | $1,805,308 |  |  | $1,405,306 |  |  | $1,739,011 |  |  | $1,234,846 |  |  | $1,411,154 |
| SUBTRACT Grant Fair Value of Equity Awards Made During Current Year(a) |  |  | ($3,833,108) |  |  | ($3,124,444) |  |  | ($4,630,341) |  |  | ($2,942,637) |  |  | ($8,994,889) |  |  | $0 |  |  | ($1,169,352) |  |  | ($719,959) |  |  | ($1,051,440) |  |  | ($658,333) |  |  | ($962,952) |
| ADD Year End Fair Value of Equity Awards Made During Current Year(b) |  |  | $2,096,033 |  |  | $2,457,454 |  |  | $5,294,178 |  |  | $3,254,974 |  |  | $9,337,528 |  |  | $0 |  |  | $​482,698 |  |  | $568,766 |  |  | $1,205,238 |  |  | $728,209 |  |  | $668,806 |
| ADD Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards(c) |  |  | ($1,148,160) |  |  | ($1,421,814) |  |  | ($1,016,462) |  |  | ($2,470,476) |  |  | $0 |  |  | $0 |  |  | ($​95,541) |  |  | ($252,244) |  |  | ($274,828) |  |  | ($189,171) |  |  | ($64,142) |
| ADD Change in Fair Value of Equity Awards Granted in Prior Years that Vested in Current Year(d) |  |  | $313,596 |  |  | ($500,768) |  |  | ($1,988,334) |  |  | ($226,155) |  |  | $0 |  |  | ($18,351) |  |  | $44,901 |  |  | ($124,563) |  |  | ($211,562) |  |  | ($63,754) |  |  | ($83,186) |
| ADD Fair Value at Vesting of Equity Awards Made During Year That Also Vested During Year(e) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $141,315 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |
| SUBTRACT Fair Value at the End of the Prior Year of Equity Awards that Were Forfeited During Year(f) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($7,358,716) |  |  | ($​218,005) |  |  | $0 |  |  | $0 |  |  | $0 |  |  | ($197,641) |
| Total Adjustments Related to Equity Awards |  |  | ($2,571,639) |  |  | ($2,589,573) |  |  | ($2,340,959) |  |  | ($2,384,295) |  |  | $483,954 |  |  | ($7,377,066) |  |  | ($​955,299) |  |  | ($527,999) |  |  | ($332,592) |  |  | ($183,048) |  |  | ($639,115) |
| Compensation Actually Paid Total |  |  | $2,531,827 |  |  | $1,870,227 |  |  | $3,599,763 |  |  | $1,818,313 |  |  | $10,513,388 |  |  | ($7,088,313) |  |  | ​$​850,008 |  |  | $877,307 |  |  | $1,406,419 |  |  | $1,051,797 |  |  | $772,039 |
(a) | Represents the grant date fair value of equity-based awards made during the fiscal year.
(b) | Represents the year-end fair value of equity awards that were made during the fiscal year.
(c) | Represents the change in fair value during the fiscal year of equity-based awards granted in prior fiscal years that were still unvested as of year-end.
(d) | Represents the change in fair value since prior year-end of equity-based awards granted in prior fiscal years that vested during the current fiscal year.
(e) | Represents the fair value on the vesting date of equity-based awards that vested in the same year as granted. In 2020, Dr. Blanchard received a grant of RSUs for her service as interim Chief Executive Officer between February and April 2020, which RSUs fully vested upon her permanent appointment as President and CEO in April 2020.
(f) | Represents the prior year-end fair value of equity awards that were forfeited by other PEOs who terminated during the year. Mr. Darling passed away unexpectedly in early 2020, and unvested equity awards were forfeited upon his death. Ms. Cheung resigned in August 2020 and all unvested equity awards were forfeited upon her resignation. Mr. Levitz resigned his position as Executive Vice President, Chief Financial Officer and Treasurer in June 2024, and separated from service with the Company as of December 31, 2024, at which time all of his unvested equity awards were forfeited.
Compensation Actually Paid vs. Total Shareholder Return |  |  | The chart below shows CAP for each year along with investment values based on total shareholder return for both the Company and the NASDAQ Biotechnology Index. |  |  |  |
Compensation Actually Paid vs. Net Income |  |  | The chart below shows CAP for each year along with Company net income for each year. |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  | The chart below shows CAP for each year along with Company revenues for each year. |  |  |  |
Total Shareholder Return Vs Peer Group |  |  | The chart below shows CAP for each year along with investment values based on total shareholder return for both the Company and the NASDAQ Biotechnology Index. |  |  |  |
Tabular List, Table |  |  | The following table sets forth what we consider to be the most important financial performance measures in how CAP was linked to Company performance during 2024. Key Financial Measures Revenue Adjusted Net Income Adjusted EBITDA Adjusted net income and Adjusted EBITDA are non-GAAP financial measures. Please refer to the detailed definitions of these key financial measures, and the reconciliations of these measures to the most directly comparable financial measures calculated and presented in accordance with GAAP, in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission at www.sec.gov. |  |  |  |
Total Shareholder Return Amount |  |  | $ 32 | 44 | 57 | 69 | 87
Peer Group Total Shareholder Return Amount |  |  | 114 | 115 | 111 | 125 | 126
Net Income (Loss) |  |  | $ (56,000,000) | $ (83,000,000) | $ (15,000,000) | $ 4,000,000 | $ (24,000,000)
Company Selected Measure Amount |  |  | 120,000,000 | 167,000,000 | 156,000,000 | 148,000,000 | 130,000,000
PEO Name | Mr. Darling | Dr. Blanchard | Dr. Blanchard | Dr. Blanchard | Dr. Blanchard | Dr. Blanchard |
Additional 402(v) Disclosure |  |  | The table below summarizes the option fair values and related assumptions used to calculate NEO CAP for fiscal year 2024.
| Valuation Purpose for PVP |  |  | ANIK Stock Price |  |  | ANIK Option Exercise Price |  |  | Expected Term (years) |  |  | Stock Price Volatility |  |  | Risk-Free Rate |  |  | Dividend Yield |  |  | Option Fair Value |
| Year-end 2023 |  |  | $22.66 |  |  | $28.14 – $47.60 |  |  | 3.31 – 4.66 |  |  | 48.20% |  |  | 3.87% – 3.98% |  |  | 0% |  |  | $5.08 – $8.38 |
| 2024 Vesting |  |  | $24.27 – $25.79 |  |  | $28.14 – $47.60 |  |  | 2.82 – 4.08 |  |  | 41.50% – 46.90% |  |  | 3.52% – 4.30% |  |  | 0% |  |  | $3.37 – $9.36 |
| Year-end 2024 |  |  | $16.46 |  |  | $27.98 – $29.60 |  |  | 3.41 – 5.73 |  |  | 42.00% |  |  | 4.29% – 4.42% |  |  | 0% |  |  | $2.92 – $4.72 |
Measure:: 1 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Revenue |  |  |  |
Measure:: 2 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Adjusted Net Income |  |  |  |
Non-GAAP Measure Description |  |  | Adjusted net income and Adjusted EBITDA are non-GAAP financial measures. Please refer to the detailed definitions of these key financial measures, and the reconciliations of these measures to the most directly comparable financial measures calculated and presented in accordance with GAAP, in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission at www.sec.gov. |  |  |  |
Measure:: 3 |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Name |  |  | Adjusted EBITDA |  |  |  |
Non-GAAP Measure Description |  |  | Adjusted net income and Adjusted EBITDA are non-GAAP financial measures. Please refer to the detailed definitions of these key financial measures, and the reconciliations of these measures to the most directly comparable financial measures calculated and presented in accordance with GAAP, in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission at www.sec.gov. |  |  |  |
Dr. Blanchard [Member] |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
PEO Total Compensation Amount |  |  | $ 5,103,466 | $ 4,459,800 | $ 5,940,722 | $ 4,202,608 | $ 10,029,434
PEO Actually Paid Compensation Amount |  |  | 2,531,827 | 1,870,227 | 3,599,763 | 1,818,313 | 10,513,388
Mr. Darling [Member] |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
PEO Total Compensation Amount |  |  |  |  |  |  | 288,753
PEO Actually Paid Compensation Amount |  |  |  |  |  |  | (7,088,313)
PEO | Dr. Blanchard [Member] | Equity Awards Adjustments |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (2,571,639) | (2,589,573) | (2,340,959) | (2,384,295) | 483,954
PEO | Dr. Blanchard [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (3,833,108) | (3,124,444) | (4,630,341) | (2,942,637) | (8,994,889)
PEO | Dr. Blanchard [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 2,096,033 | 2,457,454 | 5,294,178 | 3,254,974 | 9,337,528
PEO | Dr. Blanchard [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (1,148,160) | (1,421,814) | (1,016,462) | (2,470,476) | 0
PEO | Dr. Blanchard [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0 | 0 | 141,315
PEO | Dr. Blanchard [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 313,596 | (500,768) | (1,988,334) | (226,155) | 0
PEO | Dr. Blanchard [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0 | 0 | 0
PEO | Mr. Darling [Member] | Equity Awards Adjustments |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | (7,377,066)
PEO | Mr. Darling [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | 0
PEO | Mr. Darling [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | 0
PEO | Mr. Darling [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | 0
PEO | Mr. Darling [Member] | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | 0
PEO | Mr. Darling [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | (18,351)
PEO | Mr. Darling [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  |  |  |  |  | (7,358,716)
Non-PEO NEO | Equity Awards Adjustments |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (955,299) | (527,999) | (332,592) | (183,048) | (639,115)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (1,169,352) | (719,959) | (1,051,440) | (658,333) | (962,952)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 482,698 | 568,766 | 1,205,238 | 728,209 | 668,806
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | (95,541) | (252,244) | (274,828) | (189,171) | (64,142)
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 0 | 0 | 0 | 0 | 0
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | 44,901 | (124,563) | (211,562) | (63,754) | (83,186)
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |  |  |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |  |  |
Adjustment to Compensation, Amount |  |  | $ (218,005) | $ 0 | $ 0 | $ 0 | $ (197,641)

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v + Details
Name: | ecd_Additional402vDisclosureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=anik_DrBlanchardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=anik_MrDarlingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsAdjsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |